Abstract
Blocking of IL-23 has shown a profound effect on patient outcomes in psoriasis. The current IL-23 binding monoclonal antibodies show differences in dosing regimens, pharmacokinetics, affinity for the target, and efficacy outcomes in the clinic. The goal of the current work is to use a mechanistic pharmacokinetics/pharmacodynamics mathematical model to estimate projected free IL-23 neutralization for the different therapeutic molecules and connect it to clinical efficacy outcomes. The meta-analysis indicates a sigmoid-like relationship and suggests that the best current anti-IL23 antibodies are close to saturating the efficacy that can be achieved by this pathway in psoriasis.
Competing Interest Statement
The author is an employee of Pfizer, Inc. The author declares no other competing interests for this work.
Funding Statement
No external funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The manuscript does not require oversight or approvals - all data is available in the literature.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data is available in the literature and is referenced within the manuscript.